Merit Medical Systems, Inc. Stock News

Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms. Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms.

SOUTH JORDAN, Utah, March 25, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial are scheduled for publication in the April issue of Kidney International . Twelve-month results from the randomized arm of the WAV...

SOUTH JORDAN, Utah, March 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that Chairman and Chief Executive Officer, Fred Lampropoulos, will visit the Nasdaq MarketSite in Times Square to ring the opening bell on Wednesday, March 19, 2025. The ceremony begins at 9:15 A.M. (EDT) and the bell ringing takes place at 9:30 ...

Merit Medical continues to outperform, with the share price supported by on-target financial results, incremental M&A, and positive clinical data. The company's Wrapsody stent graft showed almost best-case clinical efficacy, positioning it to capture significant market share in dialysis graft occlusion procedures. Recent acquisitions, including EsophyX Z+ and Cook Medical's lead management port...

Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants Multicenter, prospective study designed to evaluate safety and efficacy of Bloom™ Micro Occluder System for treatment of patent ductus arteriosus in premature infants

Merit Medical Systems, Inc. (MMSI) Q4 2024 Earnings Call Transcript

Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4% Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectively GAAP operating margin of 10.3%, compared to 10.4% in prior year period Non-GAAP operating margin* of 19.6%, compared to 16.6% in prior year period GAAP EPS $0.46, down 2.6%, Non-GAAP EPS* $0.93, up 25.8%, and Free cash flow*...

* Constant currency revenue is a non-GAAP financial measure. A reconciliation of this financial measure to its most directly comparable GAAP financial measure is included under the heading “Non-GAAP Financial Measure” below.